Zura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA) have been assigned a consensus rating of “Buy” from the seven analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $15.80.

A number of equities research analysts have commented on the company. Leerink Partners started coverage on Zura Bio in a research report on Monday, November 4th. They issued an “outperform” rating and a $15.00 target price on the stock. HC Wainwright restated a “neutral” rating and issued a $5.00 price objective on shares of Zura Bio in a report on Tuesday, December 24th. Chardan Capital lowered their target price on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Finally, Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a research report on Monday, November 4th.

Zura Bio Stock Performance

Shares of NASDAQ:ZURA opened at $1.41 on Thursday. Zura Bio has a 52-week low of $1.35 and a 52-week high of $6.35. The business has a fifty day moving average of $2.12 and a two-hundred day moving average of $3.26.

Insider Transactions at Zura Bio

In other news, Director Parvinder Thiara sold 1,001,633 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $2.73, for a total transaction of $2,734,458.09. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 22.10% of the company’s stock.

Hedge Funds Weigh In On Zura Bio

A number of institutional investors and hedge funds have recently made changes to their positions in ZURA. Geode Capital Management LLC lifted its stake in Zura Bio by 70.6% in the third quarter. Geode Capital Management LLC now owns 912,625 shares of the company’s stock worth $3,706,000 after acquiring an additional 377,545 shares during the last quarter. Barclays PLC raised its holdings in shares of Zura Bio by 777.1% in the 3rd quarter. Barclays PLC now owns 64,061 shares of the company’s stock valued at $260,000 after purchasing an additional 56,757 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Zura Bio during the 3rd quarter worth $71,000. Braidwell LP acquired a new position in shares of Zura Bio during the third quarter worth $10,040,000. Finally, State Street Corp increased its holdings in Zura Bio by 47.5% in the third quarter. State Street Corp now owns 395,059 shares of the company’s stock valued at $1,604,000 after buying an additional 127,300 shares during the last quarter. 61.14% of the stock is owned by institutional investors and hedge funds.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.